Hikma Pharmaceuticals PLC (HIK) - Total Assets

Latest as of June 2025: GBX5.55 Billion GBX ≈ $675.76K USD

Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) holds total assets worth GBX5.55 Billion GBX (≈ $675.76K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Hikma Pharmaceuticals PLC (HIK) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Hikma Pharmaceuticals PLC - Total Assets Trend (2002–2024)

This chart illustrates how Hikma Pharmaceuticals PLC's total assets have evolved over time, based on quarterly financial data. See Hikma Pharmaceuticals PLC shareholders equity for net asset value and shareholders' equity analysis.

Hikma Pharmaceuticals PLC - Asset Composition Analysis

Current Asset Composition (December 2024)

Hikma Pharmaceuticals PLC's total assets of GBX5.55 Billion consist of 44.1% current assets and 55.9% non-current assets.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 3.7%
Accounts Receivable GBX905.00 Million 17.6%
Inventory GBX986.00 Million 19.2%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX774.00 Million 15.1%
Goodwill GBX382.00 Million 7.4%

Asset Composition Trend (2002–2024)

This chart illustrates how Hikma Pharmaceuticals PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hikma Pharmaceuticals PLC stock valuation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Hikma Pharmaceuticals PLC's current assets represent 44.1% of total assets in 2024, a decrease from 67.9% in 2002.
  • Cash Position: Cash and equivalents constituted 3.7% of total assets in 2024, down from 12.8% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2002.
  • Asset Diversification: The largest asset category is inventory at 19.2% of total assets.

Hikma Pharmaceuticals PLC Competitors by Total Assets

Key competitors of Hikma Pharmaceuticals PLC based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
China CN¥6.49 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
China CN¥7.28 Billion
Celltrion Pharm Inc
KQ:068760
Korea ₩745.80 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
China CN¥11.80 Billion
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
China CN¥3.12 Billion

Hikma Pharmaceuticals PLC - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.24 1.66 1.76
Quick Ratio 0.72 0.98 1.12
Cash Ratio 0.00 0.00 0.00
Working Capital GBX501.00 Million GBX905.00 Million GBX808.00 Million

Hikma Pharmaceuticals PLC - Advanced Valuation Insights

This section examines the relationship between Hikma Pharmaceuticals PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.82
Latest Market Cap to Assets Ratio 0.01
Asset Growth Rate (YoY) 9.7%
Total Assets GBX5.13 Billion
Market Capitalization $42.71 Million USD

Valuation Analysis

Below Book Valuation: The market values Hikma Pharmaceuticals PLC's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Hikma Pharmaceuticals PLC's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Hikma Pharmaceuticals PLC (2002–2024)

The table below shows the annual total assets of Hikma Pharmaceuticals PLC from 2002 to 2024.

Year Total Assets Change
2024-12-31 GBX5.13 Billion
≈ $624.54K
+9.68%
2023-12-31 GBX4.68 Billion
≈ $569.42K
+4.67%
2022-12-31 GBX4.47 Billion
≈ $543.99K
+2.26%
2021-12-31 GBX4.37 Billion
≈ $531.95K
+5.73%
2020-12-31 GBX4.13 Billion
≈ $503.11K
+5.22%
2019-12-31 GBX3.93 Billion
≈ $478.17K
+12.38%
2018-12-31 GBX3.50 Billion
≈ $425.48K
+3.22%
2017-12-31 GBX3.39 Billion
≈ $412.22K
-22.35%
2016-12-31 GBX4.36 Billion
≈ $530.85K
+68.00%
2015-12-31 GBX2.60 Billion
≈ $315.98K
+15.37%
2014-12-31 GBX2.25 Billion
≈ $273.88K
+16.69%
2013-12-31 GBX1.93 Billion
≈ $234.70K
+11.50%
2012-12-31 GBX1.73 Billion
≈ $210.50K
+9.80%
2011-12-31 GBX1.58 Billion
≈ $191.71K
+41.21%
2010-12-31 GBX1.12 Billion
≈ $135.76K
+9.10%
2009-12-31 GBX1.02 Billion
≈ $124.44K
+5.82%
2008-12-31 GBX966.46 Million
≈ $117.59K
+8.10%
2007-12-31 GBX894.04 Million
≈ $108.78K
+83.07%
2006-12-31 GBX488.36 Million
≈ $59.42K
+22.71%
2005-12-31 GBX397.96 Million
≈ $48.42K
+61.46%
2004-12-31 GBX246.48 Million
≈ $29.99K
+109.13%
2003-12-31 GBX117.86 Million
≈ $14.34K
+24.25%
2002-12-31 GBX94.86 Million
≈ $11.54K
--

About Hikma Pharmaceuticals PLC

LSE:HIK UK Drug Manufacturers - Specialty & Generic
Market Cap
$42.71 Million
GBX351.00 Billion GBX
Market Cap Rank
#22426 Global
#170 in UK
Share Price
GBX1585.00
Change (1 day)
-0.56%
52-Week Range
GBX1191.00 - GBX1930.00
All Time High
GBX2408.28
About

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more